MARC record from Internet Archive

LEADER: 06301cam 2200985Ia 4500
001 ocn663097544
003 OCoLC
005 20200514221051.0
008 100909s2010 gw a ob 000 0 eng d
006 m o d
007 cr cn|||||||||
040 $aGW5XE$beng$epn$cGW5XE$dEBLCP$dOCLCQ$dCOO$dN$T$dCUS$dHNK$dVAM$dE7B$dOCLCQ$dYDXCP$dOCLCQ$dOCLCF$dOCLCQ$dIDEBK$dBEDGE$dOCLCQ$dNLGGC$dNUI$dDEBSZ$dOCLCQ$dVT2$dOCLCO$dOCLCQ$dUAB$dESU$dOCLCQ$dIBK$dIOG$dOCLCO$dOCLCA$dCEF$dU3W$dAU@$dOCLCO$dWYU$dOCLCA$dYOU$dLEAUB$dOCLCO$dCNTRU$dUKAHL$dOCLCQ$dOCLCA$dOCLCQ$dVLB$dOCLCA
015 $aGBA982612$2bnb
016 7 $a101524883$2DNLM
016 7 $a015352822$2Uk
019 $a501085919$a647854280$a654388488$a709624482$a771373791$a771373793$a985045127$a1005749730$a1044295345$a1056401986$a1060861433$a1075044717$a1087363490$a1105589624$a1148140299
020 $a9783642012228
020 $a3642012221
020 $z9783642012211
020 $z3642012213
035 $a(OCoLC)663097544$z(OCoLC)501085919$z(OCoLC)647854280$z(OCoLC)654388488$z(OCoLC)709624482$z(OCoLC)771373791$z(OCoLC)771373793$z(OCoLC)985045127$z(OCoLC)1005749730$z(OCoLC)1044295345$z(OCoLC)1056401986$z(OCoLC)1060861433$z(OCoLC)1075044717$z(OCoLC)1087363490$z(OCoLC)1105589624$z(OCoLC)1148140299
037 $a978-3-642-01221-1$bSpringer$nhttp://www.springerlink.com
050 4 $aRC262$b.S63 2010
050 4 $aRC261$b.R35 v.184 2010
060 4 $aW1$bRE106P v.184 2010
060 4 $aQZ 267$bS635 2010
072 7 $aMED$x062000$2bisacsh
072 7 $aHEA$x039030$2bisacsh
082 04 $a616.994061$222
245 00 $aSmall molecules in oncology /$cUwe M. Martens (ed.).
260 $aHeidelberg ;$aLondon :$bSpringer,$c℗♭2010.
300 $a1 online resource (xvi, 238 pages) :$billustrations
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aRecent results in cancer research ;$v184
504 $aIncludes bibliographical references.
505 0 $aProtein kinase inhibitors -- Imatinib mesylate -- Erlotinib -- Axitinib -- Lapatinib -- Sorafenib -- Sunitinib -- Dasatinib -- Nilotinib -- Bosutinib -- Epigenetic modifiers -- Decitabine -- 5-Azacytidine/Azacitidine -- Cell cycle inhibitors -- Bortezomib -- Temsirolimus -- Danusertib (formerly PHA-739358): a novel combined pan-aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor -- BI_2536: targeting the mitotic kinase polo-like kinase 1 (Plk1) -- Other novel agents -- Imetelstat (GRN163L): Telomerase-based cancer therapy -- GDC-0449: targeting the hedgehog signaling pathway.
588 0 $aPrint version record.
520 $aExtensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.
650 0 $aCancer$xMolecular aspects.
650 0 $aAntineoplastic agents.
650 0 $aCancer$xTreatment.
650 12 $aNeoplasms$xdrug therapy.
650 22 $aAntineoplastic Agents$xtherapeutic use.
650 22 $aAzacitidine$xtherapeutic use.
650 22 $aProtein Kinase Inhibitors$xtherapeutic use.
650 7 $aMEDICAL$xOncology.$2bisacsh
650 7 $aHEALTH & FITNESS$xDiseases$xCancer.$2bisacsh
650 7 $aMe decine.$2eclas
650 7 $aAntineoplastic agents.$2fast$0(OCoLC)fst00810595
650 7 $aCancer$xMolecular aspects.$2fast$0(OCoLC)fst00845397
650 7 $aCancer$xTreatment.$2fast$0(OCoLC)fst00845538
650 7 $aCytostatikum$2gnd
650 7 $aKleines Moleku l$2gnd
650 07 $aKleines Moleke ul.$2swd
655 4 $aElectronic books.
700 1 $aMartens, Uwe M.
776 08 $iPrint version:$tSmall molecules in oncology.$dHeidelberg ; London : Springer, ℗♭2010$z9783642012211$z3642012213$w(DLC) 2009933609$w(OCoLC)495596327
830 0 $aRecent results in cancer research ;$v184.
856 40 $3ProQuest Ebook Central$uhttp://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=511577
856 40 $3ebrary$uhttp://site.ebrary.com/id/10361988
856 40 $3EBSCOhost$uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=312922
856 40 $3MyiLibrary$uhttp://www.myilibrary.com?id=635382
856 40 $3Scholars Portal$uhttp://books.scholarsportal.info/viewdoc.html?id=/ebooks/ebooks2/springer/2011-03-04/1/9783642012228
856 40 $3SpringerLink$uhttps://doi.org/10.1007/978-3-642-01222-8
856 40 $3SpringerLink$uhttps://link.springer.com/openurl?genre=book&isbn=978-3-642-01221-1
856 40 $3SpringerLink$uhttp://link.springer.com/10.1007/978-3-642-01222-8
856 40 $3SpringerLink$uhttps://link.springer.com/10.1007/978-3-642-01222-8
856 40 $3SpringerLink$uhttp://www.library.yorku.ca/e/resolver/id/1927887$zAn electronic book accessible through the World Wide Web; click for information
856 40 $3VLeBooks$uhttp://www.vlebooks.com/vleweb/product/openreader?id=none&isbn=9783642012228
856 40 $uhttps://0-link-springer-com.pugwash.lib.warwick.ac.uk/10.1007/978-3-642-01222-8$zConnect to Springer e-book
856 40 $uhttp://dx.doi.org.ezproxy.aub.edu.lb/10.1007/978-3-642-01222-8
856 4 $3Scholars Portal Books$uhttp://www.library.yorku.ca/e/resolver/id/1927886
938 $aAskews and Holts Library Services$bASKH$nAH26856340
938 $aProQuest Ebook Central$bEBLB$nEBL511577
938 $aebrary$bEBRY$nebr10361988
938 $aEBSCOhost$bEBSC$n312922
938 $aProQuest MyiLibrary Digital eBook Collection$bIDEB$ncis28843441
938 $aYBP Library Services$bYANK$n3169438
029 1 $aAU@$b000048699536
029 1 $aDEBSZ$b442814445
029 1 $aNZ1$b13521032
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 362 OTHER HOLDINGS